LT4234B - Compositions for treating mast-cell inflamatory condition - Google Patents

Compositions for treating mast-cell inflamatory condition Download PDF

Info

Publication number
LT4234B
LT4234B LT97-065A LT97065A LT4234B LT 4234 B LT4234 B LT 4234B LT 97065 A LT97065 A LT 97065A LT 4234 B LT4234 B LT 4234B
Authority
LT
Lithuania
Prior art keywords
cis
piperazinecarboxylate
bis
compound
cyclooctylene
Prior art date
Application number
LT97-065A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT97065A (en
Inventor
Ken D Rice
Jeffrey M Dener
Anthony R Gangloff
Elaine Yee-Lin Kuo
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of LT97065A publication Critical patent/LT97065A/xx
Publication of LT4234B publication Critical patent/LT4234B/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/32Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/18Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LT97-065A 1994-09-23 1997-04-10 Compositions for treating mast-cell inflamatory condition LT4234B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31226994A 1994-09-23 1994-09-23

Publications (2)

Publication Number Publication Date
LT97065A LT97065A (en) 1997-08-25
LT4234B true LT4234B (en) 1997-10-27

Family

ID=23210670

Family Applications (1)

Application Number Title Priority Date Filing Date
LT97-065A LT4234B (en) 1994-09-23 1997-04-10 Compositions for treating mast-cell inflamatory condition

Country Status (25)

Country Link
US (2) US6022969A (et)
EP (1) EP0782571A1 (et)
JP (1) JPH10506390A (et)
KR (1) KR970706267A (et)
CN (1) CN1160398A (et)
AU (1) AU694275B2 (et)
CA (1) CA2200561A1 (et)
CZ (1) CZ87097A3 (et)
EE (1) EE03525B1 (et)
FI (1) FI971171A (et)
HR (1) HRP950499B1 (et)
HU (1) HUT77770A (et)
IL (1) IL115405A (et)
LT (1) LT4234B (et)
LV (1) LV11865B (et)
MX (1) MX9702125A (et)
NO (1) NO309605B1 (et)
NZ (1) NZ294392A (et)
PL (1) PL183552B1 (et)
RU (1) RU2159229C2 (et)
SI (1) SI9520101A (et)
SK (1) SK37997A3 (et)
TW (1) TW442478B (et)
WO (1) WO1996009297A1 (et)
ZA (1) ZA958028B (et)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003267A3 (en) * 1996-07-30 2002-02-28 Arris Pharmaceutical Corp San Heteroaryl derivatives, pharmaceutical compositions containing them and process for producing them
WO1998024886A1 (en) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Mast cell protease that cleaves fibrinogen
WO1998033812A1 (en) * 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
AU8997498A (en) * 1997-09-05 1999-03-29 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitor
EP1030844A1 (en) * 1997-11-10 2000-08-30 Array Biopharma Inc. Compounds which inhibit tryptase activity
US6221914B1 (en) * 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO1999040083A2 (de) * 1998-02-06 1999-08-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Bifunktionelle tryptase-inhibitoren
US6613769B1 (en) 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
EP1115731A2 (de) * 1998-09-04 2001-07-18 Byk Gulden Lomberg Chemische Fabrik GmbH Neue pyranosen
US6362216B1 (en) 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
CN1378538A (zh) 1999-08-10 2002-11-06 比克·古尔顿·劳姆贝尔格化学公司 二氮芳辛-二酮衍生物及其作为类胰蛋白酶抑制剂的应用
JP2003509417A (ja) * 1999-09-14 2003-03-11 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼインヒビター
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
WO2001046168A1 (en) * 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
US6815557B2 (en) 1999-12-20 2004-11-09 Altana Pharma Ag Tryptase inhibitors
WO2001052883A1 (en) * 2000-01-20 2001-07-26 Amgen Inc. Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
DE60200935T2 (de) 2001-01-31 2005-09-01 Altana Pharma Ag Diazocinderivate und deren verwendung als tryptase inhibitoren
ATE364037T1 (de) * 2001-02-21 2007-06-15 Altana Pharma Ag Tryptasehemmer
WO2002066430A1 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
EP1370518A2 (en) * 2001-03-15 2003-12-17 ALTANA Pharma AG Tryptase-inhibitors
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002314165B2 (en) 2001-06-19 2008-02-21 Altana Pharma Ag Tryptase inhibitors
AU2002352382A1 (en) * 2001-12-13 2003-06-23 Kowa Company Ltd Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
US7087604B2 (en) 2002-03-08 2006-08-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
TW200524849A (en) * 2003-07-02 2005-08-01 Hoffmann La Roche Hydroxyalkylamide derivatives
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TWI414527B (zh) * 2010-10-06 2013-11-11 Ind Tech Res Inst 異山梨糖醇衍生物及包含該衍生物之液晶顯示器
CN102453037B (zh) * 2010-10-25 2014-06-25 财团法人工业技术研究院 异山梨糖醇衍生物及包含该衍生物的液晶显示器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4746737A (en) * 1985-07-26 1988-05-24 Kowa Co., Ltd. Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
NZ263084A (en) * 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
PL176941B1 (pl) * 1993-03-12 1999-08-31 Axys Pharmaceuticals Nowe peptydy i środek farmaceutyczny do leczenia immunologicznych stanów zapalnych
EP0763016B1 (en) * 1994-06-01 2000-01-26 Axys Pharmaceuticals, Inc. Compositions and methods for treating mast-cell mediated conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAUGHEY GH ET AL.: "Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase", J. PHARMACOL. EXP. THER., 1988, pages 947 - 951
HOOD ET AL.: "Immunology"
PETER VANDERSLICE ET AL.: "Molecular cloning of dog mast cell tryptase and a related protease: structural evidence of a unique mode of serine protease activation", BIOCHEMISTRY, 1989, pages 4148 - 4155
VANDERSLICE, P. ET AL.: "Human mast cell tryptase: Multiple cDNAs and genes reveal a multigene serine protease", PROC NATL ACAD SCI U S A., 1990, pages 3811 - 3815, XP002092772, DOI: doi:10.1073/pnas.87.10.3811

Also Published As

Publication number Publication date
CZ87097A3 (en) 1997-11-12
TW442478B (en) 2001-06-23
AU3718095A (en) 1996-04-09
EE03525B1 (et) 2001-10-15
HRP950499A2 (en) 1997-08-31
IL115405A (en) 2002-07-25
FI971171A0 (fi) 1997-03-20
US6211228B1 (en) 2001-04-03
LV11865A (lv) 1997-10-20
EE9700089A (et) 1997-10-15
JPH10506390A (ja) 1998-06-23
SI9520101A (en) 1997-12-31
PL319587A1 (en) 1997-08-18
SK37997A3 (en) 1998-12-02
NO309605B1 (no) 2001-02-26
WO1996009297A1 (en) 1996-03-28
NO971305D0 (no) 1997-03-20
NZ294392A (en) 1999-05-28
ZA958028B (en) 1996-04-18
LV11865B (en) 1998-01-20
RU2159229C2 (ru) 2000-11-20
AU694275B2 (en) 1998-07-16
KR970706267A (ko) 1997-11-03
HUT77770A (hu) 1998-08-28
HRP950499B1 (en) 2003-04-30
CN1160398A (zh) 1997-09-24
CA2200561A1 (en) 1996-03-28
NO971305L (no) 1997-05-06
FI971171A (fi) 1997-03-20
LT97065A (en) 1997-08-25
MX9702125A (es) 1998-04-30
EP0782571A1 (en) 1997-07-09
US6022969A (en) 2000-02-08
IL115405A0 (en) 1995-12-31
PL183552B1 (pl) 2002-06-28

Similar Documents

Publication Publication Date Title
LT4234B (en) Compositions for treating mast-cell inflamatory condition
EP0763016B1 (en) Compositions and methods for treating mast-cell mediated conditions
JP2002502850A (ja) トリプターゼ阻害物質
ES2222259T3 (es) Inhibidores de triptasa.
ES2222270T3 (es) Inhibidores de triptasa.
US6673786B1 (en) Tryptase inhibitors
EP1368317B1 (en) Tryptase inhibitors
EP1401809B1 (en) Tryptase inhibitors
AU2002253035A1 (en) Tryptase inhibitors
CA2438711A1 (en) Tryptase inhibitors
JP2004525926A (ja) トリプターゼ阻害剤

Legal Events

Date Code Title Description
PD9A Change of patent owner

Free format text: AXYS PHARMACEUTICALS, INC,385 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA 94080,US,19991015

MM9A Lapsed patents

Effective date: 20030914